Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins

Hidenori Miyamoto, Tatsuya Murakami, Kunihiro Tsuchida, Hiromu Sugino, Hidenori Miyake, Seiki Tashiro

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Introduction: Pancreatic cancer is one of the major causes of cancer-related deaths in industrialized countries. It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen 1, collagen IV, fibronectin, and laminin. Aims: To examine the role of ECM proteins in acquired resistance to anticancer drugs and proliferation regulation in pancreatic cancers. Methodology and Results: We used an in vitro model of ECM-induced chemoresistance and cell proliferation of cancer, cell lines (M1A PaCa-2, PANC-1, and Capan-1) with 3 different malignancy grades and found that resistance to cytotoxic drugs and proliferation regulation was dependent on ECM proteins. Pancreatic cancer cell lines, especially M1A PaCa-2 cells, adhering to any of the ECM proteins showed decreased cytotoxicity of anticancer drugs, except for gemcitabine. PANC-1 and Capan-1 cells adhering to fibronectin, collagen I, and collagen IV proliferated more than the controls. Conclusion: ECM proteins have important roles in acquired resistance to anticancer drugs and cell proliferation regulation of pancreatic cancer cells. Therefore, the expression of ECM proteins in pancreatic cancer specimens could provide valuable information to aid anticancer drug cytotoxicity, and gemcitabine would be useful for treatment of patients with pancreatic cancer.

Original languageEnglish
Pages (from-to)38-44
Number of pages7
JournalPancreas
Volume28
Issue number1
DOIs
Publication statusPublished - 01-01-2004

Fingerprint

Extracellular Matrix Proteins
Drug and Narcotic Control
Pancreatic Neoplasms
gemcitabine
Collagen
Neoplasms
Fibronectins
Cell Proliferation
Pharmaceutical Preparations
Cell Line
Laminin
Developed Countries
Extracellular Matrix
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Miyamoto, Hidenori ; Murakami, Tatsuya ; Tsuchida, Kunihiro ; Sugino, Hiromu ; Miyake, Hidenori ; Tashiro, Seiki. / Tumor-Stroma Interaction of Human Pancreatic Cancer : Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins. In: Pancreas. 2004 ; Vol. 28, No. 1. pp. 38-44.
@article{b2a8c6a36f1c4ee3b90fb04206d814c6,
title = "Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins",
abstract = "Introduction: Pancreatic cancer is one of the major causes of cancer-related deaths in industrialized countries. It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen 1, collagen IV, fibronectin, and laminin. Aims: To examine the role of ECM proteins in acquired resistance to anticancer drugs and proliferation regulation in pancreatic cancers. Methodology and Results: We used an in vitro model of ECM-induced chemoresistance and cell proliferation of cancer, cell lines (M1A PaCa-2, PANC-1, and Capan-1) with 3 different malignancy grades and found that resistance to cytotoxic drugs and proliferation regulation was dependent on ECM proteins. Pancreatic cancer cell lines, especially M1A PaCa-2 cells, adhering to any of the ECM proteins showed decreased cytotoxicity of anticancer drugs, except for gemcitabine. PANC-1 and Capan-1 cells adhering to fibronectin, collagen I, and collagen IV proliferated more than the controls. Conclusion: ECM proteins have important roles in acquired resistance to anticancer drugs and cell proliferation regulation of pancreatic cancer cells. Therefore, the expression of ECM proteins in pancreatic cancer specimens could provide valuable information to aid anticancer drug cytotoxicity, and gemcitabine would be useful for treatment of patients with pancreatic cancer.",
author = "Hidenori Miyamoto and Tatsuya Murakami and Kunihiro Tsuchida and Hiromu Sugino and Hidenori Miyake and Seiki Tashiro",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/00006676-200401000-00006",
language = "English",
volume = "28",
pages = "38--44",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Tumor-Stroma Interaction of Human Pancreatic Cancer : Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins. / Miyamoto, Hidenori; Murakami, Tatsuya; Tsuchida, Kunihiro; Sugino, Hiromu; Miyake, Hidenori; Tashiro, Seiki.

In: Pancreas, Vol. 28, No. 1, 01.01.2004, p. 38-44.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tumor-Stroma Interaction of Human Pancreatic Cancer

T2 - Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins

AU - Miyamoto, Hidenori

AU - Murakami, Tatsuya

AU - Tsuchida, Kunihiro

AU - Sugino, Hiromu

AU - Miyake, Hidenori

AU - Tashiro, Seiki

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Introduction: Pancreatic cancer is one of the major causes of cancer-related deaths in industrialized countries. It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen 1, collagen IV, fibronectin, and laminin. Aims: To examine the role of ECM proteins in acquired resistance to anticancer drugs and proliferation regulation in pancreatic cancers. Methodology and Results: We used an in vitro model of ECM-induced chemoresistance and cell proliferation of cancer, cell lines (M1A PaCa-2, PANC-1, and Capan-1) with 3 different malignancy grades and found that resistance to cytotoxic drugs and proliferation regulation was dependent on ECM proteins. Pancreatic cancer cell lines, especially M1A PaCa-2 cells, adhering to any of the ECM proteins showed decreased cytotoxicity of anticancer drugs, except for gemcitabine. PANC-1 and Capan-1 cells adhering to fibronectin, collagen I, and collagen IV proliferated more than the controls. Conclusion: ECM proteins have important roles in acquired resistance to anticancer drugs and cell proliferation regulation of pancreatic cancer cells. Therefore, the expression of ECM proteins in pancreatic cancer specimens could provide valuable information to aid anticancer drug cytotoxicity, and gemcitabine would be useful for treatment of patients with pancreatic cancer.

AB - Introduction: Pancreatic cancer is one of the major causes of cancer-related deaths in industrialized countries. It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen 1, collagen IV, fibronectin, and laminin. Aims: To examine the role of ECM proteins in acquired resistance to anticancer drugs and proliferation regulation in pancreatic cancers. Methodology and Results: We used an in vitro model of ECM-induced chemoresistance and cell proliferation of cancer, cell lines (M1A PaCa-2, PANC-1, and Capan-1) with 3 different malignancy grades and found that resistance to cytotoxic drugs and proliferation regulation was dependent on ECM proteins. Pancreatic cancer cell lines, especially M1A PaCa-2 cells, adhering to any of the ECM proteins showed decreased cytotoxicity of anticancer drugs, except for gemcitabine. PANC-1 and Capan-1 cells adhering to fibronectin, collagen I, and collagen IV proliferated more than the controls. Conclusion: ECM proteins have important roles in acquired resistance to anticancer drugs and cell proliferation regulation of pancreatic cancer cells. Therefore, the expression of ECM proteins in pancreatic cancer specimens could provide valuable information to aid anticancer drug cytotoxicity, and gemcitabine would be useful for treatment of patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0346157370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346157370&partnerID=8YFLogxK

U2 - 10.1097/00006676-200401000-00006

DO - 10.1097/00006676-200401000-00006

M3 - Article

C2 - 14707728

AN - SCOPUS:0346157370

VL - 28

SP - 38

EP - 44

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 1

ER -